Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > On summary of Ph 2 data, 3Q newsletter

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Jan 18, 2022 9:25am

938 Views

Post# 34327820

RE:RE:RE:On summary of Ph 2 data, 3Q newsletter

menoalittle wrote: >> In accordance with the FDA’s 2018 guidelines to industry, the patients who have achieved a Partial Response (“PR”) are being further assessed via Computerized Tomography (“CT”) scan and/or biopsy of the prostatic urethra to determine if upper tract Urothelial Cell Carcinoma (“UCC”) or prostatic urethra UCC can be detected to allow these patients to be re-categorized as CR.

Well, it sure doesn't seem to me that this "being further assessed" should (or would) take any longer than 30 to 40 days or so to get scheduled and done... but, I suppose whether they care to inform the rest of the world about those results might be another matter altogether.

Of course, I also think that some of us would probably consider the results of it to be "material news" that they would (or should) be obligated to release...